Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Madison Inc.

Division of Arrowhead Pharmaceuticals Inc.
http://www.rocheusa.com/portal/usa/madis

Latest From Anesta Corp.

Gottlieb Advances, But FDA's Future Seems Increasingly Partisan

Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.

FDA Leadership

Biopharma: Beyond the First Product

For biopharma, launching first products, and especially sudden profitability, doesn't necessarily predict which companies will succeed. Instead, an examination of stock market success shows the need to bring a succession of drugs, or at least additional indications, into clinical trials-mostly through aggressive deal-making.
BioPharmaceutical Strategy

Cephalon Learns That Risk Returns

A risk-reduction strategy has brought Cephalon success, but now brings it face to face with a new set of risks that add up to a real management dilemma. The company is waiting to hear whether FDA will approve an expanded label for Provigil, a treatment for narcolepsy. A yes could position the product for marketing to GPs. The trouble is that four big generic companies are taking aim at Provigil. Should Cephalon spend on a big sales force, or seek a co-promotion deal that, given the situation, is bound to have tough terms? This much is clear: no one escapes risk.
Strategy Clinical Trials

Drug Delivery: Moving from Platform to Product

The traditional drug-delivery business model of service for hire has fallen from popularity. Big Pharmas are doing few deals of this sort, and investors want bigger returns than fees and royalties can provide. Start-ups with drug delivery technologies are increasingly using their platforms on their own behalf, to create products they can out-license or possibly market themselves. Now content--getting the molecules to be delivered--is an issue.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Mirus Bio Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arrowhead Pharmaceuticals Inc.
  • Senior Management
  • Russell R Smestad , Pres.
    Scott A Rose, VP, Fin. & Admin.
    Jon Wolff, MD, CSO
  • Contact Info
  • Roche Madison Inc.
    Phone: (608) 316-3890
    465 Science Dr.
    Ste. C
    Madison, WI 53711
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register